Market Overview
The market size in 2017 for Global diabetes drugs market was registered to be USD 67510.43 million and expected a CAGR of 5.65% during the forecast period 2018-2024.
North America dominates the market followed by the Asia Pacific.
Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or does not produce insulin which is known as Type-1 diabetes, or because the body's cells do not respond properly to insulin which is called Type-2 diabetes mellitus, or both.
Approximately 10% of all diabetes cases are type-1, and approximately 90% of all cases of diabetes worldwide are of this type.
Scope of the Report
The market is Segmented by category (Insulin’s, Oral Anti-Diabetic Drugs, Non-Insulin Injectable drugs, and Combination drugs), by segment (Basal or Long Acting, Bolus or Fast Acting, Traditional Human Insulin drugs, Insulin Biosimilars, GLP-1 receptor agonists, Alpha-Glucosidase inhibitors, DPP4 inhibitors, SGLT2 inhibitors, etc.) and by Geography.
By Product type Insulin Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral anti-diabetic drugs
Biguanides Metformin
Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist Bromocriptin
SGLT2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides Meglitinides
Non-Insulin Injectable drugs
GLP1 receptor agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue Symlin (Pramlintide)
Combination Drugs
Insulin Combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination Janumet (Sitagliptin and Metformin HCl)
By Geography
North America
o United States
o Canada
o Rest of North America
Europe
o United Kingdom
o Germany
o France
o Russia
o Spain
o Italy
o Rest of Europe
Asia Pacific
o Australia
o China
o India
o Indonesia
o Japan
o Malaysia
o Philippines
o South Korea
o Thailand
o Vietnam
o Rest of Asia Pacific
Latin America
o Brazil
o Mexico
o Rest of Latin America
Middle East & Africa
o Saudi Arabia
o South Africa
o Iran
o Egypt
o Oman
o Rest of Middle East & Africa
Key Market Trends
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes among adults of over 18 years has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
Growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.
GDDM Rev
The United States Leads the Diabetes Drugs Market in North America
In 2017, the United States diabetes drugs market held the largest market share in North America due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in this region.
In the Asia-Pacific sector, China and India have identified as potential emerging markets due to the rising diabetic population in this region.
Region GDDM
Competitive Landscape
There have been constant innovations driven by manufacturers to compete and struggle in the market.
Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
In 2015 and 2016, Lantus global sales were down by 11%, due to competition from other new drugs, biosimilars, and it’s own brand Toujeo.
In September 2017: Insulin Tregopil, the first Oral Insulin is under development by Biocon India which is supported by JDRF and
In March 2017: Zynquista (Sotagliflozin) would be the first oral antidiabetic drug approved in the U.S. for use by adults with type-1 diabetes.
Major Players
Novo Nordisk
Sanofi
Eli Lilly
AstraZeneca
Boehringer Ingelheim
1. INTRODUCTION
1. Study Deliverables
2. Study Assumptions
3. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. Market Overview
2. Drivers
3. Restraints
4. Porter's Five Forces Analysis
1. Bargaining Power of Suppliers
2. Bargaining Power of Consumers
3. Threat of New Entrants
4. Threat of Substitute Products and Services
5. Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. By Drug
1. Oral Anti-diabetic drugs (Value and Volume 2012-2024)
1. Biguanides
1. Metformin
2. Alpha - Glucosidase inhibitors
3. Dopamine -D2 receptor agonist
1. Cycloset (Bromocriptin)
4. Sodium-glucose cotransport -2 (SGLT-2) inhibitors
1. Invokana (Canagliflozin)
2. Jardiance (Empagliflozin)
3. Farxiga/Forxiga (Dapagliflozin)
4. Suglat (Ipragliflozin)
5. Dipeptidyl peptidase-4 (DPP-4) inhibitors
1. Januvia (Sitagliptin)
2. Onglyza (Saxagliptin)
3. Tradjenta (Linagliptin)
4. Vipidia/Nesina (Alogliptin)
5. Galvus (Vildagliptin)
6. Sulfonylureas
7. Meglitinides
2. Insulins (Value and Volume 2012-2024)
1. Basal or Long Acting Insulins
1. Lantus (Insulin Glargine)
2. Levemir (Insulin Detemir)
3. Toujeo (Insulin Glargine)
4. Tresiba (Insulin Degludec)
5. Basaglar (Insulin Glargine)
2. Bolus or Fast Acting Insulins
1. NovoRapid/Novolog (Insulin Aspart)
2. Humalog (Insulin Lispro)
3. Apidra (Insulin Glulisine)
3. Traditional Human Insulins
1. Novolin/Actrapid/Insulatard
2. Humulin
3. Insuman
4. Biosimilar Insulins
1. Insulin Glargine Biosimilars
2. Human Insulin Biosimilars
3. Non-Insulin Injectable drugs (Value and Volume 2012-2024)
1. GLP-1 receptor agonists
1. Victoza (Liraglutide)
2. Byetta (Exenatide)
3. Bydureon (Exenatide)
4. Trulicity (Dulaglutide)
5. Lyxumia (Lixisenatide)
2. Amylin Analogue
1. Symlin (Pramlintide)
4. Combination Drugs
1. Combination Insulins
1. NovoMix (Biphasic Insulin Aspart)
2. Ryzodeg (Insulin Degludec and Insulin Aspart)
3. Xultophy (Insulin Degludec and Liraglutide)
2. Oral Combination
1. Janumet (Sitagliptin and Metformin HCl)
2. Geography
1. North America
1. United States (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. Canada (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. Rest of North America (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. Europe
1. France (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. Germany (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. Italy (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
4. Spain (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
5. United Kingdom (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
6. Russia (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
7. Rest of Europe (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. Latin America
1. Mexico (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. Brazil (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. Rest of Latin America (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
4. Asia-Pacific
1. Japan (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. South Korea (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. China (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
4. India (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
5. Australia (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
6. Vietnam (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
7. Malaysia (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
8. Indonesia (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
9. Philippines (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
10. Thailand (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
11. Rest of Asia Pacific (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
5. Middle East and Africa
1. Saudi Arabia (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
2. Iran (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
3. Egypt (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
4. Oman (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
5. South Africa (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
6. Rest of Middle and Africa (Value and Volume 2012-2024)
1. Oral Anti-diabetic drugs
2. Insulins
3. Non-Insulin Injectable drugs
4. Combination Drugs
5. By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
6. MARKET INDICATORS
1. Type-1 Diabetes population (2013-2024)
2. Type-2 Diabetes population (2013-2024)
7. COMPETITIVE LANDSCAPE
1. COMPANY PROFILES
1. Novo Nordisk
2. Sanofi
3. Eli Lilly
4. Takeda
5. Pfizer
6. Janssen Pharmaceuticals
7. Astellas
8. Boehringer Ingelheim
9. Merck And Co.
10. AstraZeneca
11. Bristol Myers Squibb
12. Novartis
2. COMPANY SHARE ANALYSIS
1. Novo Nordisk
2. Sanofi
3. Eli Lilly
4. AstraZeneca
5. Astellas
6. Janssen Pharmaceuticals
7. Merck And Co.
8. Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
+1 888 709 8757
Chat With Us